gb PHARM DPYD*2A
The CE IVD real-time PCR kit is intended for detection of mutation DPYD*2A (IVS14+1G>A) in gene for dihydropyrimidine dehydrogenase in human genomic DNA by real-time PCR method (allelic discrimination).
We are an EN ISO 13485 certified EU-located company developing and producing CE IVD real-time PCR kits.
Our in vitro diagnostics fall into five categories: clinical genetics, hematology, pharmacogenetics, oncology and microbiology.
Our typical partners are end-users of the RT-PCR kits (mostly in CZ and SK), business partners and distributors. We are looking for business partners and/or distributors worldwide who can fit the portfolio of our products, either the whole or a part of it, to their sales strategy (see here).
The CE IVD real-time PCR kit is intended for detection of mutation DPYD*2A (IVS14+1G>A) in gene for dihydropyrimidine dehydrogenase in human genomic DNA by real-time PCR method (allelic discrimination).
The CE IVD real-time PCR kit is intended for detection of mutation CYP2C9*2, CYP2C9*3 and VKORC1 G1639A in human genomic DNA by real-time PCR method (allelic discrimination).
The CE IVD real-time PCR kit is intended for prognosis assessment in CLL patients by analysis of cDNA (reverse transcribed RNA) samples of human B lymphocytes obtained from peripheral blood. The kit is based on reverse transcription together with quantitative real-time polymerase chain reaction (qRT-PCR) using fluorescently labelled probes.
Your request has been sent.
Your cycler has not been included in the list?
Send us the type of your cycler and we will find a solution for you.
Your request has been sent.
Thank you for your inquiry
Thank you for your inquiry
Your registration has been sent.
Thank you for your inquiry
Price will be calculated based on your exact location within 2 working days.